Asthma and stem cell therapy

World Journal of Stem Cells, Год журнала: 2025, Номер 17(2)

Опубликована: Фев. 24, 2025

The global incidence of asthma, a leading respiratory disorder affecting more than 235 million people, has dramatically increased in recent years. Characterized by chronic airway inflammation and an imbalanced response to airborne irritants, this condition is associated with elevated levels inflammatory factors symptoms such as dyspnea, cough, wheezing, chest tightness. Conventional asthma therapies, corticosteroids, long-acting β-agonists, anti-inflammatory agents, often evoke diverse adverse reactions fail reduce hospitalization rates over the long term effectively. These limitations have prompted researchers explore innovative therapeutic strategies, including stem cell-related interventions, offering hope those afflicted incurable disease. In review, we describe characteristics cells critically assess potential challenges cell-based therapies improve disease management treatment outcomes for other diseases.

Язык: Английский

Extracellular Vesicles from Mesenchymal Stem Cells: Potential as Therapeutics in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Biomedicines, Год журнала: 2024, Номер 12(12), С. 2848 - 2848

Опубликована: Дек. 14, 2024

Background/Objectives: Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by the accumulation of triglycerides within hepatocytes, which can progress to more severe conditions, such as metabolic steatohepatitis (MASH), may include progressive fibrosis, leading cirrhosis, cancer, and death. This goal this review highlight recent research showing potential mesenchymal stem cell-derived extracellular vesicles (MSC-EVs) in reducing key pathogenic pathways MASLD or MASH. Methods: Relevant published studies were identified using PubMed with one following search terms: MASLD, MASH, NAFLD, NASH, exosome, vesicle (EV), therapy, and/or cells (MSC). The primary literature subsequently downloaded summarized. Results: Using vitro vivo models, MSC-EVs have been found counteract oxidative stress, a significant contributor injury suppress progression, including steatosis, inflammation, and, few instances, fibrosis. Some these outcomes attributed specific EV cargo components microRNAs proteins. Thus, enriched types molecules improved therapeutic efficacy for MASLD/MASH represent novel approach potentially halt reverse process. Conclusions: are attractive agents treating MASLD/MASH. Further necessary validate clinical applicability human MASH patients, focusing on optimizing delivery strategies identifying that targeted components.

Язык: Английский